NasdaqCM - Nasdaq Real Time Price USD

Autonomix Medical, Inc. (AMIX)

2.3000

+0.2200

+(10.68%)

As of 11:46:20 AM EDT. Market Open.

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, being held May 20-23, 2025 in Paris, France. Details of the poster p

GlobeNewswire 4 days ago

AMIX
+10.68%
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THE WOODLANDS, TX, April 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix’s Board of Directors approved the grant of an inducement stock option on April 17, 2025 to purchase 5,000 shares of the Company’s common stock, to a new non-e

GlobeNewswire 10 days ago

AMIX
+10.68%
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed a

GlobeNewswire 12 days ago

AMIX
+10.68%
Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has engaged U.S. and international-based medical experts in interventional radiology and ca

GlobeNewswire 20 days ago

AMIX
+10.68%
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Netherlands. Details of the poster presentatio

GlobeNewswire 25 days ago

AMIX
+10.68%
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology

Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications THE WOODLANDS, TX, March 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing

GlobeNewswire last month

AMIX
+10.68%
Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation

Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF”) Generator On track for Investigational Device Exemption (“IDE”) submission and, if approved, U.S. clinical trial initiation in 2025 for pancreatic cancer pain Milestone advances proprietary sensing and ablation catheter technology into a fully integrated transvascular treatment platform THE WOODLANDS, TX, March 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Me

GlobeNewswire last month

AMIX
+10.68%
Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

THE WOODLANDS, TX, March 06, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced its abstract has been accepted for poster presentation at the 2025 Society of Interventional Radiology (“SIR”) Annual Scientific Meeting being held March 29-April 2, 2025 in in Nashville, Tennessee. Deta

GlobeNewswire last month

AMIX
+10.68%
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the LSI USA ’25 Emerging Medtech Summit on Tuesday, March 18, 2025 at 7:35 AM PT. In addition to the presentation, management will be

GlobeNewswire last month

AMIX
+10.68%
Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting

Presentation to highlight Autonomix’s catheter-based technology and key findings from lead-in patients in ongoing human clinical trial in pancreatic cancer pain patients THE WOODLANDS, TX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will present its technology and lead-in subject findings in a podium presentation at the 2025 Cardiovasc

GlobeNewswire 2 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here THE WOODLANDS, TX, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, presented the top five reasons of why he believes the investment comm

GlobeNewswire 2 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer with topline data on track for 1H 2025 Continued solid execution on milestones with several design locks and key development objectives met in the quarter Company remains on track to submit an Investigational Device Exemption (“IDE”), and if approved, will initiate US clinical trials in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medica

GlobeNewswire 2 months ago

AMIX
+10.68%
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Brad Hauser, CEO of Autonomix, shared feedback from the recently held 43rd Annual J.P. Morgan Healthcare Conferenc

GlobeNewswire 3 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company advancing toward submitting Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a

GlobeNewswire 3 months ago

AMIX
+10.68%
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Live video webcast on Wednesday, January 22nd at 4:00 PM ET THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, January 22, 2025 at 4:00 PM ET. As part of the event, Brad Ha

GlobeNewswire 3 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting

THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced its abstract has been accepted for poster presentation at the SIO 2025 Annual Scientific Meeting, being held January 30 – February 3, 2025 in Las Vegas, NV. Details of the accepted abstract are as follows

GlobeNewswire 3 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology

Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass THE WOODLANDS, TX, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies

GlobeNewswire 3 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

Autonomix Medical, Inc. Biotech/Med Device executive Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE

GlobeNewswire 4 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source Company expects to submit an Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing

GlobeNewswire 4 months ago

AMIX
+10.68%
Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the closing of its previously announced underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $10.0 million, prior to deducting underwriting discounts and commissions and offering expenses, which amount in

GlobeNewswire 4 months ago

AMIX
+10.68%

Performance Overview

Return	AMIX	S&P 500 (^GSPC)
YTD	-38.83%	-6.62%
1-Year	-96.58%	+7.69%
3-Year	-98.49%	+28.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Autonomix Medical, Inc. (AMIX)

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation

Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting

Autonomix Medical, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology

Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

Performance Overview